RAPT: CCR4 Inhibition Presses On For Now With Oncology Focus
RAPT Therapeutics suffered a setback in February 2024 with the FDA putting a clinical hold on two of its studies. The company is developing a drug for the treatment of patients with atopic dermatitis and asthma. Data from phase 2b study, using zelnecirnon, is expected in Q3 of 2024; potential for FDA clinical hold to be removed.
Seeking Alpha · 18h ago
Merck Q2 Earnings Preview: We Need To Talk About Keytruda's LOE
Seeking Alpha · 23h ago
Daily Dividend Report: CTAS,ROL,WFC,MRK,BDX
NASDAQ · 1d ago
What Lies in Store for Healthcare ETFs in Q2 Earnings?
NASDAQ · 1d ago
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
Merck & Co Inc shared topline results from its Phase 2b/3 clinical trial of clesrovimab. The antibody is designed to protect infants from respiratory syncytial virus (RSV) disease. The drug met its primary safety and efficacy endpoints in the trial.
Benzinga · 1d ago
Merck declares $0.77 dividend
Seeking Alpha · 1d ago
Press Release: Merck Announces Fourth-Quarter 2024 Dividend
Dow Jones · 2d ago
Dow Analyst Moves: MRK
NASDAQ · 2d ago
Billionaires Are Loading Up on This Surging Dow Stock. Should You?
Merck stock has outperformed the Dow Jones Industrial Average in 2024. The pharmaceutical giant is known for its cancer immunotherapy drug Keytruda. Kenneth Griffin's Citadel Advisors purchased 1.25 million shares of Merck in the second quarter of 2024. Merck's stock has seen a 16.8% surge year-to-date. The company's stock offers a solid dividend yield of 2.45%.
The Motley Fool · 2d ago
Merck Announces Fourth-Quarter 2024 Dividend
Barchart · 2d ago
Merck RSV therapy succeeds in infants in challenge to Sanofi, Astra
Seeking Alpha · 2d ago
Merck's Clesrovimab RSV Candidate Meets Key Phase 2b/3 Study Goals
Dow Jones · 2d ago
Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants
Merck announces positive topline results from its Phase 2b/3 clinical trial evaluating clesrovimab to protect infants from respiratory syncytial virus (RSV) disease. The drug met its primary safety and efficacy endpoints, including reducing medically attended lower respiratory infections. RSV is the leading cause of hospitalization for healthy infants.
Barchart · 2d ago
Veeva Systems: Headwinds Have Created Opportunity And Pent-Up Demand
Seeking Alpha · 2d ago
Should You Pick Johnson & Johnson Stock At $155 After Q2 Beat?
NASDAQ · 2d ago
Should You Pick Roche Stock Around $40 After Positive Data For Its Obesity Drugs?
NASDAQ · 2d ago
Elanco (ELAN) Stock Declines After Sale of Aqua Business
NASDAQ · 3d ago
Healthcare 2024 Second Half Outlook
Seeking Alpha · 3d ago
Validea Detailed Fundamental Analysis - MRK
NASDAQ · 3d ago
Weekly Report: what happened at MRK last week (0715-0719)?
Weekly Report · 3d ago
Webull provides a variety of real-time MRK stock news. You can receive the latest news about Merck & Co through multiple platforms. This information may help you make smarter investment decisions.
About MRK
Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products include therapeutic and preventive agents, sold by prescription, for the treatment of human disorders. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3, an inhibitory canonical Notch ligand. Its lead candidate, Restoret, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site signaling pathway.